TORONTO--(EON: Enhanced Online News)--SQI Diagnostics Inc. (TSX-V:SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”) today announces that its technology is being highlighted in a presentation and poster being presented today by Bristol-Myers Squibb at the Bioassays and Bioanalytical Method Development Conference in Berkeley, CA.
“Isotyping Therapeutic Protein Immunogenicity in an Automated Multiplexed Assay”
The information to be highlighted will include performance data comparing a custom built immunogenicity assay for a Bristol-Myers Squibb drug, on four different species, using SQI’s Ig_PLEX technology. The data will compare this assay to a standard ELISA assay as well as another competitive multiplexing technology to demonstrate SQI’s superior performance.
“SQI is excited to see its custom anti-drug antibody products showcase the power of Ig_PLEX to the pharmaceutical and CRO communities in this public forum,” said Andrew Morris, CEO of SQI Diagnostics. “We know the utility of this technology, as shared by Bristol-Myers Squibb, and we are proud to see our technology’s strength conveyed to the rest of the method development community by such a respected partner.”
SQI and Bristol-Myers Squibb are separately presenting a poster titled “Isotyping Therapeutic Protein Immunogenicity in an Automated Multiplexed Assay” highlighting the performance of SQI’s technology platform. The poster will detail data representing the benefits to drug development companies of using SQI’s Ig_PLEX tests in their clinical studies. The poster highlights the use of SQI’s Ig_PLEX tests and automated systems to produce equivalent or superior performance to ELISA and other multiplexing technologies, providing proof of SQI’s Ig_PLEX technology as a leading method for immunogenicity testing. Other benefits to using SQI’s technology include: providing quantitative results for multiple anti-drug antibody isotypes in a single test; significantly improving work-flow and reducing labour costs; and, enabling drug developers to align with the emerging regulatory guidelines surrounding immunogenicity testing worldwide.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality.
For more information about SQiDlite and SQI Diagnostics’ suite of biopharma and clinical diagnostic products and services please visit www.sqidiagnostics.com, or contact SQI at: email@example.com.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “is subject to” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the ability of our patents to adequately protect our rights or permit us to gain or keep any competitive advantage, and our ability to market and sell our novel multiplexing technologies and detection platforms. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.